BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder characterized by deficiency in endoglin, an angiogenic protein. The net effect of endoglin expression on cancer outcomes from animal studies has proven controversial. We evaluated whether reduced systemic endoglin levels, expected in patients diagnosed with HHT, impacted clinical outcomes for cancer. METHODS: A retrospective cohort analysis using Surveillance, Epidemiology, and End Results-Medicare was conducted to evaluate the effect of HHT on survival among patients diagnosed with breast, colorectal, lung, or prostate cancer between 2000 and 2007 (n = 540,520). We generated Kaplan-Meier survival curves and Cox models to compare the effect of HHT on all-cause survival for a composite of the four cancers, and separate models by cancer, adjusting for demographic variables, cancer type, cancer stage, and comorbidities. RESULTS: All-cause survival analysis for a composite of the four cancers showed an adjusted HR of 0.69 [95% confidence interval (CI) of 0.51-0.91; P = 0.009] for HHT, indicating significantly improved survival outcome. When stratified by cancer type, HHT diagnosis showed a significant protective effect among breast cancer patients with an adjusted HR of 0.31 (95% CI, 0.13-0.75; P = 0.009). CONCLUSIONS: There was a significant association between HHT and improved survival outcome for a composite of patients with breast, prostate, colorectal, and lung cancer, and in analysis stratified by cancer, the association was significant for HHT patients with breast cancer. IMPACT: This study supports the hypothesis that systemically educed endoglin expression is associated with improved survival outcome in multiple cancers, and suggests that anti-endoglin antibody therapy may have broad-based application.
BACKGROUND:Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder characterized by deficiency in endoglin, an angiogenic protein. The net effect of endoglin expression on cancer outcomes from animal studies has proven controversial. We evaluated whether reduced systemic endoglin levels, expected in patients diagnosed with HHT, impacted clinical outcomes for cancer. METHODS: A retrospective cohort analysis using Surveillance, Epidemiology, and End Results-Medicare was conducted to evaluate the effect of HHT on survival among patients diagnosed with breast, colorectal, lung, or prostate cancer between 2000 and 2007 (n = 540,520). We generated Kaplan-Meier survival curves and Cox models to compare the effect of HHT on all-cause survival for a composite of the four cancers, and separate models by cancer, adjusting for demographic variables, cancer type, cancer stage, and comorbidities. RESULTS: All-cause survival analysis for a composite of the four cancers showed an adjusted HR of 0.69 [95% confidence interval (CI) of 0.51-0.91; P = 0.009] for HHT, indicating significantly improved survival outcome. When stratified by cancer type, HHT diagnosis showed a significant protective effect among breast cancerpatients with an adjusted HR of 0.31 (95% CI, 0.13-0.75; P = 0.009). CONCLUSIONS: There was a significant association between HHT and improved survival outcome for a composite of patients with breast, prostate, colorectal, and lung cancer, and in analysis stratified by cancer, the association was significant for HHTpatients with breast cancer. IMPACT: This study supports the hypothesis that systemically educed endoglin expression is associated with improved survival outcome in multiple cancers, and suggests that anti-endoglin antibody therapy may have broad-based application.
Authors: Francisco Gómez-Esquer; David Agudo; Fernando Martínez-Arribas; María-José Nuñez-Villar; José Schneider Journal: Anticancer Res Date: 2004 May-Jun Impact factor: 2.480
Authors: Eduardo Pérez-Gómez; Gaelle Del Castillo; Santibáñez Juan Francisco; Jose Miguel López-Novoa; Carmelo Bernabéu; Miguel Quintanilla Journal: ScientificWorldJournal Date: 2010-12-14
Authors: Michael S Gordon; Francisco Robert; Daniela Matei; David S Mendelson; Jonathan W Goldman; E Gabriela Chiorean; Robert M Strother; Ben K Seon; William D Figg; Cody J Peer; Delia Alvarez; Bonne J Adams; Charles P Theuer; Lee S Rosen Journal: Clin Cancer Res Date: 2014-09-26 Impact factor: 12.531
Authors: Toni K Choueiri; M Dror Michaelson; Edwin M Posadas; Guru P Sonpavde; David F McDermott; Andrew B Nixon; Yingmiao Liu; Zhenhua Yuan; Ben K Seon; Meghara Walsh; Manoj A Jivani; Bonne J Adams; Charles P Theuer Journal: Oncologist Date: 2018-09-06
Authors: Toni K Choueiri; Yousef Zakharia; Sumanta Pal; Judit Kocsis; Russell Pachynski; Alexandr Poprach; Andrew B Nixon; Yingmiao Liu; Mark Starr; Jing Lyu; Kouros Owzar; Mollie deShazo; Primo Lara; Lajos Geczi; Thai H Ho; Meghara Walsh; Bonne Adams; Liz Robertson; Mohamed Darif; Charles Theuer; Neeraj Agarwal Journal: Oncologist Date: 2021-04-29
Authors: Kira Young; Eric Tweedie; Barbara Conley; Jacquelyn Ames; MaryLynn FitzSimons; Peter Brooks; Lucy Liaw; Calvin P H Vary Journal: PLoS One Date: 2015-04-24 Impact factor: 3.240